Insight Molecular Diagnostics Advances GraftAssureDx FDA Review
NASHVILLE, Tennessee, August 10, 2026 Insight Molecular Diagnostics, Inc. (iMDx) reported second-quarter 2026 results and provided an update on...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
NASHVILLE, Tennessee, August 10, 2026 Insight Molecular Diagnostics, Inc. (iMDx) reported second-quarter 2026 results and provided an update on...
BRISBANE, Calif. | June 16, 2026 CareDx, Inc. has announced the publication of the second analysis from the Kidney...
NASHVILLE, Tenn., June 11, 2026 Insight Molecular Diagnostics, Inc. (Nasdaq: IMDX) announced that the American Journal of Transplantation has...
